← All trials
NCT05241275
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2022
- Primary completion
- Jun 1, 2026
- Completion date
- Jun 1, 2026
- First posted
- Feb 15, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 75
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- Boehringer IngelheimCollaborator
- Duke UniversityOverall official - principal investigator
- Duke UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.